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ABSTRACT 
Objective: The main objective of the study is to prognosticate the market research on usage of antibiotics in serious infections and corresponding 
with the clinicians based on the preference order of drugs. 
Methods: A prospective observational study was conducted for a period of six months in various hospitals in AndhraPradesh. Analysis on 
Piperacillin + Tazobactum, Cefepime and Meropenem drugs used for resistant isolates were identified to be the most effective antibacterial agents. 
Respondents reviewed three drugs based on the dosage, duration, type of case and any specific conditions to avoid these drugs. 
Results: Out of total Sample size (N=128) when assessed Piperacillin+Tazobactum (84.38%), Cefepime (12.50%), Meropenem (3.12%). The most 
prevalent type of case and usage of doctors to treat UTI (25.00%), Sepsis (17.86%), Severe Sepsis (14.29%), CRTI, LRTI (8.33%) and others 
(34.52%) were reported. 
Conclusion: Piperacillin+Tazobactum is used as Ist line, Cefepime as IInd line followed by Meropenem as IIIrd
Keywords: N- respondents (doctors), UTI, CRTI, LRTI, Sepsis, Antibiotic Resistance and Competitor. 
 line drug. When a competitor enters the 
market they should consider the availability of the products (domestic & generic) as per the cost effectiveness reliable to the patients which has 




Antibiotics are the medications used to treat and in some cases 
prevent bacterial infections. According to the CDC [1] (Centers for 
Disease Control and Prevention), outpatient antibiotic overuse in the 
USA is a particular problem in the South-East. The antibiotic resistance 
continues to be a serious public health threat worldwide, according to 
the ECDC (European Centre for Disease Prevention and Control). In a 
statement issued in 19th November 2013, the ECDC informed that an 
estimated 25,000 people die each year in the European Union from 
antibiotic-resistant bacterial infections. New ECDC data has shown 
that there has been a considerable increase over the last four years of 
combined resistance to multiple antibiotics in E. coli and 
Drug profile 
Klebsiella 
pneumoniae in over one third of EU and EEA (European Economic 
Area) nations. Consumption of carbapenems, a major class of last-line 
antibiotics, increased significantly from 2010 to 2013 [1]. 
Meropenem 
It belongs to the class carbapenem [2]. Parent antibiotic 
Thienamycin derived from Streptomyces cattleya act by inhibiting 
cell wall synthesis which is active against both gram positive and 
gram negative bacteria. They are not active against methicillin-
resistant staphylococci (MRSA), Enterococcus bacteria. Readily 
penetrates the cell wall of most gram positive bacteria and gram 
negative bacteria to reach PBP 2, 3 & 4 of E.coli and Pseudomonas 
aeruginosa, PBP 1, 2 & 4 of Staphylococcus aureus [3, 4]. 
Meropenem is mainly used to treat Bacterial meningitis [5] which 
increases the stability to degrade by Dehydropeptidase-I. eg: 
Merrem I.V, Meronem. Protein binding of about 2%.Metabolism 
excreted is unchanged; Route of elimination is 70% IV in urine over 
12 hrs, t1/2 
Cefepime 
[6] 1 hr adults &children 2 yrs of age. Toxicity in Mice and 
Rats I.V dose of (2200-4000mg/kg) causes dyspnea, convulsions.  
It belongs to fourth generation cephalosporins [7] which are more 
resistant to β lactamases. Cefepime is usually reserved to treat 
severe nosocomial pneumonia infections caused by multi-resistant 
micro-organisms (eg Pseudomonas aeruginosa) [8, 9, 10] empirical 
treatment of febrile neutropenia which is active against streptococci, 
methicillin-sensitive staphylococci but it is not active against MRSA. 
Cefepime has excellent penetration for CNS infections. eg: Maxipime, 
Maxcef, Cepimex. Protein Binding is of about 20%; Metabolism 
occurs in liver NMP and rapidly converted to NMP-N-Oxide.  
Route of elimination t1/2
Piperacillin+Tazobactum 
 2(0.3) hrs, Clearance [11] is 120 mL/min 
[Healthy adult male receiving a single 30-minute IV infusions of 
cefepime], 3.3 +/- 1.0 mL/min/kg [Pediatric patients (2 months-11 
years of age) receiving a single IV dose], Toxicity over dosage 
includes seizures, encephalopathy. 
It belongs to the class Carboxypencillins and Ureidopencillins. They 
are acid liable, inhibits by cell wall synthesis and susceptible to β - 
lactamase [12, 13] and is not recommended for the treatment of 
bacterial meningitis. They act synergistically with amino glycoside 
antibiotics and is a good choice to treat surgical wound infections 
[14]. Volume of distribution is 101mL/min/kg [intravenous 
administration of 50 mg/kg (5-minute infusion) in neonates], not 
metabolized, Route of elimination as with other penicillins, Pipracil 
is eliminated primarily by glomerular filtration and tubular 
secretion; it is excreted rapidly as unchanged drug in high 
concentrations in the urine. Because Pipracil is excreted by the 
biliary route as well as by the renal route, it can be used safely in 
appropriate dosage in patients with severely restricted kidney 
function.t1/2 36-72 minutes. Clearance [15] is 32 - 41 mL/min / 
1.73 m2, 124 - 160 mL/min / 1.73 m2 
MATERIALS AND METHODS 
[older pediatric patients]. Used 
in combination with piperacillin to broaden the spectrum of 
piperacillin antibacterial action. Eg: Zosyn, Tazocin and Pipracil. 
Study Area and Period 
The population of this study constitutes respondents in Andhra 
Pradesh, which covers all the super-speciality and multi-speciality 
hospitals. The Sample size constitutes of [N=128] per quarter were 
documented from 15 areas in AndhraPradesh for a period of 6 
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months. The Sampling Unit consists of clinicians based on their 
specializations.  
Study Design 
The doctors prescribing the three most effective anti-bacterial drugs 
were Meropenem, Cefepime, Piperacillin+Tazobactum used in 
serious infections consists of General Physicians, Critical Care, 
General Surgeons, Gastro Enterologist, Orthopaedics, Paediatrician, 
Nephrologists, Gynecologists, Anaesthesist. 
Data Collection Management 
Research Methodology is the systematic way to solve the problem. 
Data collection plays an important role in survey analysis which is of 
two modes. Probably I selected both the modes. Firstly, Primary data 
a structured questionnaire was designed for the collection from the 
targeted respondents. Secondly, the other sources of data were from 
the text books and website has been the major source for reviewing 
journals, articles, blogs etc. An accurate data has been collected both 
qualitatively and quantitatively from the clinicians. Analyzing the 
depth of the research topic based on the given time framework, I 
selected (N=128) respondents. The collected data was tabulated and 
analyzed using percentage analysis which refers to ratio between 
two or more data and describes their relationship; descriptive 
statistics were used in order to meet the objective of the study. 
Research Instrument 
The research instrument is to analyze the preference order of the 
three anti-bacterial drugs (Piperacillin+Tazobactum, Cefepime, 
Meropenem). In order to make my research specific and to address 
the issue in the marketers point of view, conducted analysis on the 
three most efficacious drugs 
• In what type of cases does the doctor prefer these drugs? 
• The prescribed dosage and duration of these drugs during the 
diseased condition? 
• Are there any specific conditions to avoid these drugs? 
Ethical Consideration 
Prior to the study an ethical clearance was obtained from various 
hospitals. Before data collection an official letter from the college 
explaining the purpose of the survey was submitted to the hospital 
administration for the collaboration during data collection and 
support of the administration in prior meeting with the doctors. 
RESULTS AND DISCUSSION 
When assessed on usage of antibiotics in serious infections, Out of 
128 respondents reviews it was found out that 
 Usage of drugs based on the specialization, number of doctors, 
and super, multi-speciality hospitals were taken into 
consideration 
General Physician's out of 32 clinicians, Piperacillin + Tazobactum 
(24 doctors), Cefepime (8 doctors). Critical Care out of 16 clinicians 
Piperacillin + Tazobactum (12 doctors), Cefepime (4 doctors). 
General Surgeons total 12 doctors prescribe Piperacillin + 
Tazobactum. Gastro-Enterologist out of 12 doctors, Piperacillin + 
Tazobactum (8 doctors) and Meropenem 
(4 doctors). Orthopaedic Surgeons total 16 doctors prescribe 
Piperacillin + Tazobactum. Paediatricians out of 8 clinicians, 
Piperacillin + Tazobactum (4 doctors) and Cefepime (4 doctors). 
Nephrologist total 8 doctors prescribe Piperacillin + Tazobactum. 
Gynecologist total 16 doctors prescribe Piperacillin + Tazobactum. 
Anaesthesist total 8 doctors prescribe Piperacillin + Tazobactum. 
From the above data we can estimate that the most specialized 
doctors in super and multi speciality hospitals uses 
• Piperacillin+Tazobactum as Ist
• Cefepime as II
 line of drugs. 
nd
• Meropenem as III
 line of drugs. 
rd
Note: When patients do not respond to usual medicines known as I
 line of drugs. 
st 
line of drugs, doctors prescribe IInd or IIIrd
Drugs 
 line of drugs which 
usually costs more 
 Analysis of drugs used based on the % usage of doctors, % 
usage based on the specialization 
Considering all the above details of 128 respondents, tabular 
columns were drawn in Table 1 and Table 2 below respectively 
 
Table 1: Drugs used based on % usage of 128 doctors 
% Usage of 128 Doctors 




Table 2: Percentage of Drugs used based on the Specialization* 
Specialization* Meropenem Cefepime Piperacillin+Tazobactum 
% of usage based on specialization* % of usage based on specialization* % of usage based on specialization* 
General Physician 0 25 75 
Critical Care 0 25 75 
General Surgeon 0 0 100 
Gastro -Enterologist 33.33 0 66.7 
Orthopaedic Surgeons 0 0 100 
Paediatrics 0 50 50 
Nephrologist 0 0 100 
Gynecologist 0 0 100 
Anaesthesist 0 0 100 
 
3.125% of doctors prescribe Meropenem: Out of which (33.33%) of 
Gastro Enterologist prescribe Meropenem to treat against 
complicated appendicitis and peritonitis caused by (E.coli, Klebsiella 
pneumoniae, Pseudomonas aeruginosa, Bacteroides, 
Peptostreptococcus species). 12.5% of doctors prescribe Cefepime: 
Out of which (25%) of General Physician's prescribe Cefepime for 
Febrile Neutropenia (E.coli, Klebsiella pneumoniae, Proteus 
mirabilis). (25%) of Critical Care clinicians treat Respiratory tract 
infections and Uncomplicated skin/Skin structure infections caused 
by Staphylococcus aureus, (50%) of Paediatrician treat against 
Nosocomial pneumoniae caused by Pseudomonas aeruginosa, 
Streptococcus pneumonia. 
84.38% of doctors prescribe Piperacillin +Tazobactum: Out of which 
(75%) of General Physician's treat Respiratory Tract Infections 
(RTI), Pneumonia (Klebsiella pneumoniae, Streptococcus pneumonia), 
and Diabetic foot infections (Staphylococcus aureus). (75%) of 
Critical Care treat Respiratory infections and Uncomplicated 
skin/Skin structure infections caused by Staphylococcus aureus 
(100%) of General Surgeons and Anaesthesist prescribe to treat skin 
infections caused by Staphylococcus aureus, Pneumonia (Klebsiella 
pneumoniae, Streptococcus pneumonia) (66.7%) of Gastro 
Enterologist prescribe to treat Moderate Sepsis, 
Appendicitis (complicated by rupture or abscess) 
and peritonitis caused by piperacillin-resistant, β - lactamase 
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producing strains of E.coli and the following member of the 
B.fragilis group: B.fragilis, B.ovatus, B.thetaiotaomicron, B.vulgatus 
(100%) of Orthopaedic Surgeons prescribe to treat Bone and Joint 
Infections caused by (Staphylococci, Streptococci). (50%) of 
Paediatrician prescribe to treat Neonatal sepsis and Nosocomial 
pneumonia caused by Acinetobacter baumanii, Haemophilus 
influenzae, Kpneumoniae, Pseudomonas aeruginosa (Note: 
Nosocomial pneumonia caused by Pseudomonas aeruginosa should 
be treated with an aminoglycoside). (100%) of Nephrologist treat 
Urinary Tract Infections caused by E.coli, Klebsellia. (100%) of 
Gynecologist treats Postpartum endometritis/Pelvic inflammatory 
disease caused by piperacillin-resistant β-lactamase producing 
strains of Escherichia coli. were depicted from Table 1 (Figure 1) and 
Table 2 (Figure 2) respectively, 
 
 
Fig. 1: % Usage of 128 Doctors treating Serious Infections. 
 
 
Fig. 2: % Usage based on the specialization 
 
Usage of drugs based on the type of case, dosage and duration 
prescribed by the doctors 
Meropenem:  
Label claim (500mg, 1.0gm, 2.0gm), Single therapy, (15 -30 min), I.V 
8hrs. 
• Gastro Enterologist prescribes 1.0gm/kg I.V, TID (7-10 days) 
under severe abdomen Sepsis, Acute Abdomen infections, and 
Pancreatitis conditions.  
Cefepime: Label Claim (250mg, 500mg, and 1000mg), Single 
therapy, (15-30 min),I.V/I.M 12hrs. 
• General Physician prescribes 1.0 gm /kg I.V, BID (5-7 days) under 
LRTI /UTI, CAP, SSTI infections, Initial sepsis and Febrile 
Neutropenia. 
• Critical Care prescribes 1.0gm /kg I.V, BID (5 -7 days) under RTI, 
Skin and soft tissue Infections and uncomplicated sepsis conditions. 
• Paediatrician prescribes 500mg /kg I.V BID (7-10 days) under 
LRTI and Nososcomal Pneumonia. 
Piperacillin + Tazobactum: Label Claim (1.0gm + 125 mg, 2.0gm + 
250 mg, 4.5gm + 500mg), Combination therapy, 30 min, I.V 8hrs, not 
used in children below 12 years of age. 
• General Physician prescribes 4.5 gm + 0.5 gm /kg I.V TID (7-10 
days) under RTI, UTI, Abdomen sepsis, Pneumonia Infections and 
Diabetic foot infections. 
• Critical Care prescribes 4.5 gm + 0.5 gm /kg I.V TID (7-10 days) 
under uncomplicated sepsis, Pneumonia, UTI, LRTI and Intra 
abdominal Sepsis.  
• General Surgeon prescribes 4.5 gm + 0.5 gm /kg I.V TID (7-10 
days) under skin and soft tissue infections and RTI conditions. 
• Gastro Enterologist prescribes 4.5 gm + 0.5 gm /kg I.V TID (7-10 
days) under moderate sepsis conditions. 
• Orthopaedic Surgeons prescribes 4.5 gm + 0.5 gm/kg I.V TID (7-
10 days) under Joint replacement surgeries and Bone-Joint 
infections. 
• Paediatrician prescribes 4.5 gm + 0.5 gm/kg I.V TID (7-10 days) 
under Neonatal sepsis, LRTI, Nosocomial Pneumonia, UTI and sepsis 
conditions. 
• Nephrologist prescribes 4.5 gm + 0.5 gm/kg I.V TID (7-10 days) 
under UTI infections  
• Gynecologist prescribes 2.25 gm + 0.25 gm/kg I.V TID (4-5days) 
under UTI, Pelvic and Open wound / surgical infections. 
• Anaesthesist prescribes 4.5 gm + 0.5 gm/kg I.V TID (7-10 days) 
under Pneumonia,UTI,LRTI and severe sepsis conditions 
Analysis based on the type of case and % Usage of doctors 
From the above information analysis based on the type of case and 
% Usage of doctors is shown below in Table 3 and Figure 3 is 
illustrated 
 
Table 3: Based on the type of case and % Usage of Doctors 
 Based on the type of case % Usage of Doctors 
Sepsis 17.86 






Fig. 3: Based on the type of case and % of usage of doctors 
 
Any Specific conditions to avoid these drugs 
Meropenem is avoided especially when the patient is suffering from 
Seizures whereas Cefepime and Piperacillin + Tazobactum are 
avoided under Hypersensitivity reactions and Renal failure (In such 
cases the dosage level is reduced by the Nephrologist for Clearance).  
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CONCLUSION 
The drugs used for the treatment of serious infections (sepsis, 
severe sepsis, LRT, CRTI, UTI, others) were studied based on their 
pharmacological actions and market analysis which also include the 
thorough survey of usage of each above mentioned drug in the 
profilitic manner. The results were concluded based on the 
prescription of the disease. Piperacillin+Tazobactum was considered 
to be the Ist line, Cefepime as the IInd line followed by Meropenem as 
the IIIrd 
1. Frieden TR. Antibiotic Resistance and the Threat to Public 
Health:testimony Before the Subcomm. On Health of the House 
Committee on Energy and Commerce, 111th Cong., 2nd Sess. 
2010 April 28. 
line drug. Finally I conclude when a competitor enters into 
the market they should consider the market availability of the 
products (domestic & generic) as per the cost and reliable to the 
patients based on less adverse effects, antibiotic resistance and ease 
of intake to the patients as per the demographical conditions. 
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